ValuEngine upgraded shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a sell rating to a hold rating in a report released on Thursday, June 21st.
Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their target price on Pacira Pharmaceuticals from $40.00 to $43.00 and gave the company a neutral rating in a research report on Tuesday, April 10th. Canaccord Genuity set a $34.00 price objective on Pacira Pharmaceuticals and gave the company a hold rating in a report on Wednesday, May 30th. Oppenheimer reaffirmed a hold rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 17th. Wedbush cut their price objective on Pacira Pharmaceuticals from $72.00 to $80.00 and set an outperform rating for the company in a research report on Monday, April 9th. Finally, BMO Capital Markets lifted their target price on Pacira Pharmaceuticals from $31.00 to $34.00 and gave the company a market perform rating in a research report on Monday, April 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have assigned a buy rating to the stock. Pacira Pharmaceuticals has an average rating of Hold and an average price target of $45.00.
PCRX stock opened at $32.05 on Thursday. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $51.10. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 1.00.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, May 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The firm had revenue of $74.61 million for the quarter, compared to the consensus estimate of $73.92 million. Pacira Pharmaceuticals had a negative net margin of 11.45% and a negative return on equity of 5.81%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. sell-side analysts expect that Pacira Pharmaceuticals will post -0.57 EPS for the current fiscal year.
In other news, CAO Kristen Marie Williams sold 2,040 shares of the stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $33.02, for a total value of $67,360.80. Following the completion of the sale, the chief accounting officer now owns 19,272 shares in the company, valued at $636,361.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David M. Stack sold 18,406 shares of the firm’s stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $36.28, for a total value of $667,769.68. Following the sale, the chief executive officer now owns 91,831 shares of the company’s stock, valued at approximately $3,331,628.68. The disclosure for this sale can be found here. Insiders have sold 49,093 shares of company stock worth $1,700,983 over the last quarter. 5.90% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in PCRX. venBio Select Advisor LLC lifted its holdings in Pacira Pharmaceuticals by 102.1% during the 1st quarter. venBio Select Advisor LLC now owns 1,715,072 shares of the company’s stock worth $53,424,000 after buying an additional 866,500 shares during the last quarter. PointState Capital LP lifted its holdings in shares of Pacira Pharmaceuticals by 71.1% in the 1st quarter. PointState Capital LP now owns 2,038,153 shares of the company’s stock worth $63,488,000 after purchasing an additional 847,146 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Pacira Pharmaceuticals in the 4th quarter worth approximately $24,644,000. Nexthera Capital LP bought a new stake in shares of Pacira Pharmaceuticals in the 1st quarter worth approximately $14,909,000. Finally, Summit Trail Advisors LLC lifted its holdings in shares of Pacira Pharmaceuticals by 2,888.3% in the 1st quarter. Summit Trail Advisors LLC now owns 399,688 shares of the company’s stock worth $400,000 after purchasing an additional 386,313 shares during the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.